RHEUMATOLOGY SERVICES

Rheumatoid arthritis
comprehensive testing capabilities

labcorp
Rheumatoid Arthritis

Rheumatoid arthritis (RA) affects an estimated 1.5 million people in the United States.1 For most people with RA, early diagnosis and treatment can control joint pain and swelling and lessen joint damage. Labcorp is your single source solution for RA diagnosis, disease activity monitoring and management of treatment.

RA DIAGNOSIS
- RA Specific: RheumAssure® RA4x6, SeroNeg RA4x4, RA Profile with reflex to SeroNeg RA4x4

BASELINE DISEASE ACTIVITY
- Vectra (Baseline)

TREATMENT DECISION
- Biologic
- Thiopurine
- Methotrexate

PRE-TREATMENT TESTING
- Biologic: CBC, Metabolic Panel, QuantiFERON®-TB Gold Plus, Hepatitis B Screening, Hepatitis C Screening, Pre-Biologic Screening Profile
- Thiopurine: CBC, TPMT Enzymes or TPMT Genotype, Hepatitis B Screening, Hepatitis C Screening
- Methotrexate: CBC, Metabolic Panel, Hepatitis B Screening, Hepatitis C Screening

MONITOR DISEASE ACTIVITY
- Vectra (Monitor)

TREATMENT MONITORING
- MTX Polyglutamates (MTX PGs)
- Hydroxychloroquine (HCQ)
- Biologic Drug Concentration and Antibody Testing (DoseASSURE™)

TREATMENT MANAGEMENT
- Quantify active drug levels
- Identify immunogenicity
- Adjust dosing and frequency
- Consider co-therapy
- Switch Treatment

Trusted Source for the Rheumatology Specialist

Labcorp offers a comprehensive testing menu and numerous service benefits to support the needs of a rheumatology practice:
- Experienced medical affairs professionals are available for consultation and educational programs
- Multiple connectivity options
- Nearly 2,000 patient service centers nationwide
- Extensive network of managed care health plans
- Broad capabilities in autoimmune testing
- Labcorp offers a dedicated Rheumatology Services Hotline 800-338-1918
RA Diagnosis

Early rheumatoid arthritis (RA) diagnosis and initiation of disease-suppressing therapy may improve clinical outcomes and reduce the accrual of joint damage and disability. Labcorp offers several RA-specific markers that, when used in combination, provide industry-leading sensitivity and help support an early diagnosis of RA.

Prognosis is dependent on early, accurate diagnosis and establishing an effective treatment plan. Diagnosis and classification of RA has relied heavily on anti-cyclic citrullinated peptide (Anti-CCP) and rheumatoid factor (RF) IgM. New markers are available to better identify patients with RA, stratify patients for risk of joint destruction and/or radiographic progression, and to monitor disease activity and effectiveness of treatment.

RheumAssure®
Labcorp’s RheumAssure panel contains Rheumatoid Factor (RF), Cyclic Citrullinated Peptide (CCP) Antibodies, and 14-3-3 eta protein tests.
- Used together, these three markers are able to diagnose established RA with a sensitivity of 88%-96% and early RA with a sensitivity of 78%-91%.
- Elevation of one or more RheumAssure markers is consistent with an RA diagnosis and if all three markers are negative, a diagnosis is less likely.

RAdx6 Profile
The RAdx6 combines four novel markers (14-3-3 eta, Anti-Sa, Anti-CEP-1, and Anti-CarP) with two traditional markers (RF IgM and Anti-CCP) to enhance diagnosis in early or established RA, and help predict disease severity.
- Disappearance or decrease of 14-3-3 eta and/or Anti-Sa with treatment is associated with less radiographic progression.
- In pre-clinical RA, Anti-CEP-1 with Anti-CCP antibodies significantly raises the risk of imminently developing clinical RA.
- Anti-CarP may predict the development of RA independently of Anti-CCP and may be present years before the onset of symptoms in RA.

SeroNeg RAdx4 Profile and RA Profile (RF and Anti-CCP) reflex to SeroNeg RAdx4
Diagnostic and prognostic panels designed to complement traditional RF and Anti-CCP testing. The profile consists of 14-3-3 eta, Anti-Sa, Anti-CEP-1, and Anti-CarP.
- Enhances RA diagnosis and helps predict disease severity.
- Helps identify RA in Anti-CCP-negative and IgM RF-negative patients and in the diagnosis of early RA.

Disease activity monitor and prognostic tool
Vectra® by Labcorp

Achieving a state of disease remission in rheumatoid arthritis (RA) is a primary treatment goal. Until the desired treatment target is reached, drug therapy should be adjusted at least every 3 to 6 months. The desired treatment target should be maintained throughout the remaining course of the disease. Vectra provides an objective measure of RA inflammation and can be used to complement other disease activity measures.

Vectra is an advanced blood test that objectively measures inflammation caused by RA. Vectra provides a personalized score by measuring 12 biomarkers and incorporates information on age, gender and adiposity to measure RA inflammation and predict future risk of radiographic progression.

Vectra Cardiovascular Risk provides a personalized assessment of inflammation to predict an RA patient’s risk of a cardiovascular event in the next 3 years.

Vectra is intended to be used at therapy initiation, change in drug therapy, and to monitor a patient once they achieve low disease activity.
RA Treatment Monitoring

Although RA treatment is multifaceted, medications play an important role in patient management. Newly developed laboratory assays aid physicians in monitoring use and maximizing effectiveness of both disease-modifying anti-rheumatic drugs (DMARDs) and biologics.

Methotrexate Polyglutamates
Methotrexate (MTX) is subject to wide pharmacokinetic variability. About 30% of patients do not respond to MTX treatment or experience adverse effects. Testing for MTX PGs can help assess patient compliance and determine correct dosing to achieve therapeutic levels and clinical response.

Hydroxychloroquine, Whole Blood
Hydroxychloroquine (HCQ) concentrations may be useful in achieving maximal clinical benefit while minimizing long-term retinal toxicity in lupus and other chronic autoimmune diseases. Monitoring HCQ may also improve adherence.

Thiopurine Drug
Thiopurine-related testing may be used to assess dosing before and during treatment, as well as to identify patients who may be at risk for drug toxicity. The FDA-approved label recommends testing consideration for the most common TPMT gene mutations (genotype) or TPMT activity (phenotype) before beginning treatment due to potentially severe bone marrow toxicity.

Monitoring Biologics

Therapeutic drug monitoring for biologics is a valuable tool to evaluate dose and tailor dose adjustments to your individual patient. Dosing by weight and empiric dose adjustment may be inefficient and suboptimal. DoseASSURE, Labcorp’s portfolio of biologics monitoring assays, may help physicians optimize biological therapy using a personalized, patient-specific approach by:

- Aiding in titrating doses and adjusting frequency to maximize effectiveness
- Helping differentiate non-compliance and undertreatment from other causes of lack of response
- Assisting in preventing and managing loss of response due to immunogenicity
- Minimizing cost to patient by avoiding unhelpful dose escalation
- Predicting which patients are likely to retain long-term response

Biologic Therapy
Labcorp offers serum measurement of drug and anti-drug antibodies for patients on biologic drug therapy. Drug and anti-drug antibody levels provide the pharmacokinetic and immunogenic assessment that discerns the underlying mechanism of an inadequate response to a biologic drug. Testing may be ordered at any time during therapy, though sample collection before the next infusion or injection is recommended.

Patient on Biologic*
### Rheumatoid Arthritis and Related Testing

<table>
<thead>
<tr>
<th>Test Name</th>
<th>Test No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>14-3-3 eta, Rheumatoid Arthritis</td>
<td>504550</td>
</tr>
<tr>
<td>Anti-Carbamylated Protein (CarP) Antibody</td>
<td>520311</td>
</tr>
<tr>
<td>Anti-CCP (Cyclic Citrullinated Peptide) Antibodies</td>
<td>164914</td>
</tr>
<tr>
<td>Anti-CEP-1 Ab, IgG (RDL)</td>
<td>520133</td>
</tr>
<tr>
<td>Anti-Sa Ab, IgG (RDL)</td>
<td>520081</td>
</tr>
<tr>
<td>Hydroxychloroquine, Whole Blood</td>
<td>504814</td>
</tr>
<tr>
<td>Methotrexate polyglutamates</td>
<td>504104</td>
</tr>
<tr>
<td>QuantIFERON®-TB Gold Plus</td>
<td>182879</td>
</tr>
<tr>
<td>RA Profile with reflex to SeroNeg RAdx4 Profile</td>
<td>520304</td>
</tr>
<tr>
<td>RAdx6 Profile</td>
<td>504509</td>
</tr>
<tr>
<td>RheumAssure®</td>
<td>504509</td>
</tr>
<tr>
<td>Rheumatoid Factor (RF)</td>
<td>006502</td>
</tr>
<tr>
<td>SeroNeg RAdx4 Profile</td>
<td>520305</td>
</tr>
<tr>
<td>Thiopurine Metabolites</td>
<td>503800</td>
</tr>
<tr>
<td>Thiopurine Methyltransferase (TPMT), Enzyme Activity, Erythrocytes</td>
<td>510750</td>
</tr>
<tr>
<td>TPMT and NUDT15 Genotyping</td>
<td>512300</td>
</tr>
<tr>
<td>Vectra®</td>
<td>504965</td>
</tr>
<tr>
<td>Vectra® with CV Risk</td>
<td>504980</td>
</tr>
</tbody>
</table>

#### DoseASSURE™

- Adalimumab and Anti-Adalimumab Antibody (Serial Monitor), DoseASSURE™ ADL | 503890
- Certolizumab and Anti-Certolizumab Antibody, DoseASSURE™ CTZ | 504627
- Etanercept and Anti-Etanercept Antibody (Serial Monitor), DoseASSURE™ ETN | 504245
- Golimumab and Anti-Golimumab Antibody, DoseASSURE™ GOL | 504563
- Infliximab and Anti-Infliximab Antibody (Serial Monitor), DoseASSURE™ IFX | 503870
- Rituximab and Anti-Rituximab Antibody, DoseASSURE™ RTX | 504355
- Ustekinumab and Anti-Ustekinumab Antibody, DoseASSURE™ UST | 504594
- Pre-Biologic Screening Profile | 144441

### References


©2023 Laboratory Corporation of America® Holdings   All rights reserved.   DX_BRO_L15239-0623-8

For more information, contact your Labcorp sales representative or scan the QR code to visit Labcorp.com.